ABSTRACT E-cadherin (CDH1) is a cell adhesion molecule that coordinates key morphogenetic processes regulating cell growth, cell proliferation, and apoptosis. Loss of CDH1 is a trademark of the cellular event epithelial to mesenchymal transition, which increases the metastatic potential of malignant cells. PTEN is a tumor-suppressor gene commonly mutated in many human cancers, including endometrial cancer. In the mouse uterus, ablation of Pten induces epithelial hyperplasia, leading to endometrial carcinomas. However, loss of Pten alone does not affect longevity until around 5 mo. Similarly, conditional ablation of Cdh1 alone does not predispose mice to cancer. In this study, we characterized the impact of dual Cdh1 and Pten ablation (Cdh1 
INTRODUCTION
Endometrial cancer is the most common malignancy of the female genital tract, affecting over 47 000 women and leading to approximately 8000 deaths in the United States each year [1] . While overall survival is relatively high for patients identified with early-stage disease, aggressive phenotypes of endometrial carcinomas do exist, and women unfortunate enough to develop them exhibit high recurrence after initial treatment and low survival rates. Several treatment options, such as hysterectomy, hormonal therapy, and combinations of radiation and chemotherapy, are effective for early-stage endometrial carcinomas; however, only limited options remain if the tumors metastasize [2] . Furthermore, effective target therapies, especially for the patients with metastatic or recurrent endometrial cancer, are unavailable because the etiology and biological mechanisms of this heterogeneous disease are not fully understood. Therefore, it is necessary to understand the etiology of endometrial tumorigenesis and metastasis in order to formulate novel treatment strategies that lead to remission and increase long-term survival.
PTEN mutations are observed in .50% of endometrial carcinomas [2] [3] [4] . Specifically, recent studies reported that loss of PTEN in epithelial cells is a critical event for endometrial tumorigenesis [5, 6] . PTEN is a major negative regulator of the phosphatidylinositol 3-kinase (PI3K) pathway, which regulates a number of cellular functions via activation of AKT [7, 8] . Thus, abnormal epithelial-specific activation of PI3K/AKT signaling initiates endometrial carcinomas [6, 9] . Mouse models harboring conditionally deleted Pten in the uterus using Pgr
Cre/þ mice induces epithelial hyperplasia as young as Postnatal Day 10 [5] . Hyperplasia further progresses to carcinomas, with invasion into the myometrium occurring by 3 mo of age [5] . However, these mice have never displayed distant metastasis to any other organs. Even though some tumor cells may disseminate into the peritoneum, these mice start dying from growing primary tumors ( [5] and Hayashi, unpublished observation).
E-cadherin (CDH1), a transmembrane glycoprotein, belongs to the cadherin superfamily of cell adhesion molecules [10] . In epithelial tissues, interactions between neighboring cells are mainly mediated by cadherins to establish and maintain cell polarity and the epithelial phenotype [11] . CDH1 is often downregulated or lost during tumor progression [12] [13] [14] [15] , leading to increased tumor invasiveness and metastasis [16] [17] [18] [19] [20] [21] . We recently reported [22] that conditional ablation of Cdh1 in the mouse uterus results in a disorganized cellular structure of the epithelium and ablation of endometrial glands. These mice are also infertile due to defects during implantation and decidualization. However, loss of Cdh1 alone in the uterus does not predispose mice to tumors [22] . Outside the uterus, conditional ablation of Cdh1 does not induce any tumors in mammary glands [23] [24] [25] or stomach [26] . Thus, these results indicate that single gene ablation in the uterus is not sufficient to understand the etiology of heterogeneous, aggressive types of endometrial carcinomas.
In the present study, we generated a mouse model in which Pten and Cdh1 were conditionally ablated in the uterus.
Specifically, we investigated whether ablation of Pten and one of the critical invasive regulators, Cdh1, accelerates endometrial neoplastic transformation and induces cell invasion and dissemination.
MATERIALS AND METHODS

Animals and Tissue Collection
Mice were maintained in the vivarium at Southern Illinois University according to the institutional guidelines for the care and use of laboratory animals. B6.129-Pgr tm2 (cre)Lyd (i.e., Pgr cre/þ ) mice were provided by Drs. Franco DeMayo and John Lydon [27] . B6.129-Cdh1 tmKem2 /J (i.e., Cdh1 flox ; Jax #005319) and B6.129S4-Pten tm1Hwu (i.e., Pten flox ; Jax #006440) were obtained from the Jackson Laboratory. The genotypes of mutant mice were determined by PCR analysis of tail genomic DNA. To assess the effects of loss of Cdh1 and/or Pten on neonatal uterine morphogenesis, female pups were necropsied on Postnatal Days 15 and 16 (n ¼ 8-20) . Two hours before euthanasia, pups received an i.p. injection of 100 mg/kg of bromodeoxyuridine (BrdU; Sigma) to assess cell proliferation. At collection, uterine tissues were fixed in fresh 4% paraformaldehyde in PBS at room temperature for 8-12 h and embedded in paraffin.
Immunohistochemical and TUNEL Analysis
Immunolocalization of BrdU, KRT8, ACTA2, PECAM1, ESR1, PGR, CTNNB1, CLDN, and pAKT was performed in cross sections (5 lm) of paraffin-embedded uterine sections using specific antibodies and a Vectastain Elite ABC Kit (Vector Laboratories) according to the manufacturer's instructions. Antibodies used in these analyses were anti-BrdU (1:200 dilution; 11 170 376 001; Roche), anti-KRT8 (1:500 dilution; MMS-162P; Covance), anti-ACTA2 (1:500 dilution; ab5694; Abcam), PECAM1 (1:100 dilution; ms728S0; Thermo Fisher), anti-ESR1 (1:100 dilution; sc-542; SantaCruz), anti-PGR (1:200 dilution; RB-9017-P0; Thermo Fisher), anti-CTNNB1 (1:250 dilution; 610513; BD), anti-claudin (1:200 dilution; 51-9000; Invitrogen), and pAKT (1:200 dilution; 3787; Cell Signaling), and negative controls were performed in which the primary antibody was substituted with the same concentration of normal IgG (Sigma). Antigen retrieval using a boiling citrate buffer was performed as described previously [22] . The TUNEL assay was performed according to the manufacturer's instructions using the ApopTag Fluorescein In Situ Apoptosis Detection Kit (Millipore).
Statistical Analysis
Overall survival rates were determined by Kaplan-Meier analysis, and P values were determined by a log-rank test using Prism 4.0 (GraphPad). All experimental data were subjected to one-way ANOVA, and differences between individual means were tested by a Tukey multiple-range test using Prism 4.0. Tests of significance were performed using the appropriate error terms according to the expectation of the mean squares for error. P , 0.05 or less was considered significant. Data are presented as least-square means with SEM.
RESULTS
Impact of Conditional Ablation of Cdh1 and Pten in Neonatal Uterus
Cdh1-and Pten-null mice show early embryonic lethality [28] [29] [30] . In order to examine the role of CDH1 and/or PTEN in the uterus, conditional ablation of Cdh1 and/or Pten was conducted to circumvent the embryonic lethal phenotype. We utilized the Pgr Cre/þ mouse line in which Cre recombinase is under the control of the Pgr promoter [27] . Pgr Cre/þ mice were crossed with Cdh1 f/f and/or Pten f/f mice to provide a tissuespecific knockout of Cdh1 and/or Pten in Pgr-expressing cells (Pgr
). Although Cre recombinase in Pgr Cre/þ mice is active in all cell types of uterus, ablation of both Cdh1 and Pten in the uterus only occurs in the epithelial cells, as endogenous CDH1 is expressed only in the uterine epithelium. It is to be noted that PGR is expressed in the oviduct, ovary, mammary gland, and pituitary.
However, we did not see any abnormalities in other tissues in
mice at 2 wk of age (data not shown). To validate CDH1 and/or PTEN ablation, CDH1 and/or PTEN immunoreactivity was determined in the uterus (Fig. 1 ). Immunohistochemical analysis confirmed that CDH1 and/or PTEN proteins were ablated by Pgr-driven Cre activity. Further, ablation of Pten either alone or with Cdh1 resulted in increased activation of AKT (pAKT) as expected ( Fig. 1) .
Ablation of Pten alone in the uterus was shown to affect viability of mice starting around 5 mo of age due to growing primary endometrial carcinomas ( [5] and Hayashi, unpublished observation). Therefore, we first examined the lifespan of control (Pgr [5] . These results indicate that ablation of Cdh1 and Pten accelerates abnormal epithelial development, cellular invasiveness, and dissemination.
Ablation of Cdh1 and Pten Stimulates Angiogenesis
To determine whether increased uterine gross morphology and uterine wet weight in Cdh1 d/d Pten d/d mice resulted from alterations in cell proliferation and/or apoptosis, we performed immunohistochemical analysis of BrdU incorporation and TUNEL assays (Fig. 4A) 
Downregulation of Steroid Hormone Receptors and Adherens and Tight Junction Molecules by Ablation of Pten and Cdh1 in the Uterus
To determine whether abnormal epithelial development affects steroid hormone receptors, we examined the expression of ESR1 and PGR by immunohistochemistry (Fig. 5A) . (Fig. 6) 8-20 ) was performed by Kaplan-Meier analysis to assess whether ablation of Cdh1 and Pten is associated with short lifespan (P , 0.0001). All mice were monitored for any sign of sickness. We euthanized mice with any sign of sickness or discomfort, and the day of euthanasia was recorded. 
DISCUSSION
Loss of CDH1 function through genetic or epigenetic mechanisms has been implicated in the progression and metastasis of numerous malignancies [20, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] . Negative or reduced expression of CDH1 is also associated with aggressive and invasive features of endometrial carcinomas [4, 13, 43, 44] . However, single-gene ablation of Cdh1 in the mouse uterus does not induce tumorigenesis [22] , indicating that loss of Cdh1 alone does not contribute to tumor initiation and progression. In the present study, we report that loss of Pten, which is one of the most widely mutated genes in endometrial cancer, along with Cdh1 ablation induces severe uterine phenotypes. We observed that uterine deletion of both Pten and Cdh1 advances mortality. We also found that ablation of Pten and Cdh1 accelerates the features of neoplastic transformation in the uterus by inducing myometrial invasion, proliferation, massive angiogenesis, and loss of steroid hormone receptors. Thus, these findings suggest that loss of Cdh1 promotes aggressive endometrial cancer phenotypes when cells are initiated by ablation of Pten.
PTEN mutations are well documented in endometrial hyperplasia with and without atypia [2] [3] [4] 45] . Loss of PTEN is likely an early event in endometrial tumorigenesis, as evidenced by its presence in precancerous lesions (simple to complex hyperplasia) [2, 3] . PTEN antagonizes the PI3K/AKT pathway by dephosphorylating PIP3, which is a second messenger that regulates the phosphorylation of AKT [8] . AKT regulates a variety of target molecules that control cell proliferation and survival. Thus, loss of PTEN results in the ability of cells to both proliferate and escape cellular senescence, and then induces hyperplastic epithelial proliferation [2] . On the other hand, most of the patients who are diagnosed with complex atypical hyperplasia and welldifferentiated endometrioid carcinomas usually show high overall survival (85% at 5 yr after initial diagnosis) following simple hysterectomy and/or progestin therapy, because tumors usually stay within the uterus [2] [3] [4] . In fact, the mouse model with uterine-specific, single-gene ablation of Pten is characterized by complex atypical hyperplasia, focal carcinomas, and metaplasia, but does not induce metastatic diseases [5] . However, high-grade endometrioid carcinomas exhibit undifferentiated and invasive features with significant morbidity [2, 46] . The present study showed that ablation of Cdh1 disrupted epithelial cellular structure in the uterus, as CDH1 is one of the main mediators of cell-to-cell adhesion in epithelial cells. When both Pten and Cdh1 were ablated in the uterus, we saw THE IMPACT OF Cdh1 AND Pten ABLATION IN THE MOUSE UTERUS the first signs of epithelial cell invasion into the myometrium, with active proliferation at an early age. Although loss of Cdh1 in the uterus also increased proliferation, we did not see any myometrial invasion in the uteri of Cdh1 d/d mice. Negative and reduced expression of CDH1 has been reported to be associated with advanced stage and poor differentiation, as well as a feature of high-grade endometrioid carcinomas [13] . Thus, these results suggest that hyperplastic endometrial cells initiated by ablation of Pten give rise to undifferentiated and invasive phenotypes, similar to advanced-stage endometrial carcinomas, when CDH1 function is inactive.
Aberrant cellular invasiveness, typically accelerated by loss of CDH1, is a hallmark property of epithelial-to-mesenchymal transition (EMT). EMT is induced by several growth factors, such as TGFb, HGF, IGF, and FGF, as well as MMPs [47] . Their receptor complexes contribute to loss of CDH1 function by inducing the expression of multiple known transcriptional repressors (SNAIL, SLUG, TWIST, and ZEB) of Cdh1. In our study, the expression of these transcriptional repressors was not altered compared to those of control tissues (data not shown), as any EMT-like character in our model stems from direct deletion of Cdh1 and not alteration of other signaling networks that operate upstream or in conjunction with CDH1 signaling. Our results showed that cellular invasiveness was observed in the uteri of Cdh1 Tumor-associated macrophages are also involved in angiogenesis [50] . In the present study, we observed complex angiogenesis in the uteri of Pten d/d mice, indicating that blood vessels had migrated and invaded into endometrium and myometrium, a hallmark feature of the developing tumor microenvironment. In support of these results, extensive uterine bleeding was observed in the uteri of these mice. Thus, it is expected that ablation of Pten and Cdh1 induces an invasive character in the cells, and invasive tumor cells have EMT potential that further potentiates invasive or migratory ability leading to establishment of the tumor microenvironment. However, the precise mechanism remains to be directly investigated.
Expression of ESR1 and PGR in endometrial cancer usually signifies that the tumors are well differentiated [51] . Loss of PTEN is likely initiated in response to known hormonal risk factors. However, expression of these receptors declines in tumors that are poorly differentiated or of higher grade [51] . Although the reasons for decreasing expression of steroid hormone receptors are not well known, women with endometrial hyperplasia and/or well-differentiated endometrial adenocarcinomas have a good response to progestin therapy [52, 53] . Thus, clinical response, overall survival, and recurrence rates generally correlate to the expression of steroid hormone receptors. The present study showed that loss of Cdh1 in the uterus is associated with the reduced expression of steroid hormone receptors. Because inactivation of CDH1 is one of the key features of invasive and aggressive cancer, CDH1 may regulate expression of steroid hormone receptors in the uterus. 
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Specifically, PGR and ESR1 were also decreased in epithelial cells by single ablation of Cdh1. Further, cell adhesion molecules, CTNNB1 and CLDN, were also suppressed. Thus, adhesive and well-differentiated epithelial cellular structures may be necessary for functional steroid hormone receptors in the uterus. Nevertheless, the results of reduced PGR and ESR1 caused by ablation of Cdh1 support the fact that high grades of endometrial cancer are unresponsive to progestin therapy. Therefore, these results suggest that ablation of Cdh1 followed by Pten deletion induces not only histological and morphological characteristics of high-grade endometrial cancer but functional and therapeutic features of this disease as well.
Collectively, the results of the present study indicate that combined loss of Cdh1 and Pten resulted in accelerated development of invasive neoplastic transformation, which shows strong resemblance to high-grade endometrial carcinomas. However, Cdh1 mice are unique and similar to high-grade endometrial carcinomas, it is necessary to further characterize invasive mechanisms relating to metastatic potential in these mice. Currently, we are characterizing invasive tumors caused by ablation of Pten and Cdh1 in a model that utilizes orthotopic implantation of transgenic uterine tissues into the uterus of wild-type syngeneic host mice to examine tumor dissemination and metastasis beyond the lifespan of the donor mice.
